In a patient with completely resected stage II (pT3 N0) ascending colon cancer that is microsatellite instability‑high and has no high‑risk features, should adjuvant immunotherapy be administered?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

No, adjuvant immunotherapy is not recommended for this patient

For a patient with completely resected stage II (pT3 N0) MSI-high colon cancer without high-risk features, observation (watchful waiting) is the appropriate management strategy—adjuvant therapy of any kind, including immunotherapy, should not be routinely offered. 1

Guideline-Based Recommendation

The 2022 ASCO guidelines explicitly state that patients with mismatch repair deficiency/microsatellite instability tumors should not be routinely offered adjuvant chemotherapy (ACT) 1. This recommendation applies to your patient for several critical reasons:

Why No Adjuvant Therapy?

  • Excellent prognosis: MSI-H stage II colon cancer has a favorable natural history with 5-year disease-free survival rates of 68%-83% with surgery alone 1
  • Lack of high-risk features: Your patient has pT3 (not T4), N0 disease without the high-risk features that would trigger consideration of adjuvant therapy
  • No proven benefit: MSI-H tumors do not derive benefit from standard fluoropyrimidine-based chemotherapy in the stage II setting 1

What Constitutes High-Risk?

The ASCO guidelines define high-risk features as: T4 tumor, fewer than 12 lymph nodes sampled, tumor perforation, clinical intestinal obstruction, poorly differentiated histology, lymphovascular invasion (LVI), perineural invasion (PNI), or grade BD3 tumor budding 1. Your patient has none of these.

The Immunotherapy Question

While recent real-world evidence suggests adjuvant immunotherapy may show promise in MSI-H colorectal cancer 2, this remains investigational and is not part of current standard guidelines. The 2025 retrospective study you referenced showed:

  • For stage II MSI-H patients: watchful waiting and immunotherapy had comparable disease-free survival (HR = 0.21,95% CI: 0.003-13.04, P = 0.463) 2
  • Overall DFS rate of 93.1% in MSI-H patients regardless of adjuvant strategy 2

This reinforces that stage II MSI-H patients without high-risk features do not require any adjuvant therapy.

Critical Caveat: If High-Risk Features Were Present

If your patient had high-risk features (particularly T4 disease or perineural invasion), the decision-making would change:

  • With high-risk features + MSI-H: If the combination of MSI-H and high-risk factors results in a decision to offer adjuvant therapy, oxaliplatin-containing chemotherapy (not immunotherapy) is recommended per ASCO guidelines 1
  • Recent data suggest perineural invasion is a particularly important adverse prognostic factor in MSI-H disease (HR 3.581 for RFS) 3

Bottom Line Algorithm

For stage II MSI-H colon cancer:

  1. No high-risk features (your patient) → Observation only
  2. T4 tumor present → Offer adjuvant chemotherapy (oxaliplatin-based if treating)
  3. Other high-risk features present → May offer adjuvant chemotherapy through shared decision-making
  4. Adjuvant immunotherapy → Not standard of care; consider only in clinical trial setting

The evidence is clear: your patient should undergo surveillance without adjuvant therapy of any kind.

References

Related Questions

Should mismatch repair (MMR) status be evaluated to guide adjuvant chemotherapy in a patient with high pre‑operative carcinoembryonic antigen (CEA) and potential high‑risk features?
What is the appropriate adjuvant systemic therapy for a patient with a stage IV moderately differentiated mucin‑secreting colon adenocarcinoma (pT4a pN1c pM1a) with positive proximal, distal, and circumferential resection margins, lymphovascular and perineural invasion, high tumor budding, and two pericolonic adipose tissue nodules?
Is it safe and effective to use bupropion (Wellbutrin) together with gabapentin in a patient who is also taking hydroxychloroquine for Sjögren’s disease?
In a patient with completely resected stage II (pathologic T3, pathologic N0) ascending colon cancer, should adjuvant chemotherapy be initiated?
How should a patient with weeks of painful erections (ischemic priapism) and recent use of tadalafil and sildenafil be managed, given the risk of permanent erectile dysfunction?
Is ibuprofen appropriate for fever reduction in otherwise healthy adults and children older than six months?
What is the appropriate initial management for a 33-year-old woman with elevated thyroid‑stimulating hormone (TSH) of 7 mIU/L, positive thyroid peroxidase (TPO) antibodies of 457 IU/mL, who presents with fatigue, hair thinning, weight gain, and dry skin?
I am a 21-year-old male who took tadalafil (10 mg) and sildenafil (30 mg) and now, 28 days later, have a persistently firm, partially engorged shaft with discoloration, numbness, prominent veins, occasional pain, and new urinary and bowel symptoms; what is the likely diagnosis and what urgent management is required?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.